Carbidopa News and Research

RSS
Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson’s disease

Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson’s disease

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

Impax Pharmaceuticals begins Phase III trial of IPX066 drug in PD patients

Impax Pharmaceuticals begins Phase III trial of IPX066 drug in PD patients

FDA approves Mylan Pharmaceuticals' Carbidopa and Levodopa tablets

FDA approves Mylan Pharmaceuticals' Carbidopa and Levodopa tablets

Phase II trial of Impax Pharmaceuticals' Parkinson’s disease drug candidate successful

Phase II trial of Impax Pharmaceuticals' Parkinson’s disease drug candidate successful

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Dopamine agonists trigger destructive behaviors

Dopamine agonists trigger destructive behaviors

Submission of NDA for Istradefylline(KW-6002), an investigational anti-Parkinson's disease drug

Submission of NDA for Istradefylline(KW-6002), an investigational anti-Parkinson's disease drug

Withdrawal of Pergolide products

Withdrawal of Pergolide products

Levodopa and pramipexole appear to be reasonable options as initial therapy for Parkinson disease

Levodopa and pramipexole appear to be reasonable options as initial therapy for Parkinson disease

IMPAX receives final FDA approval for generic version of Sinemet CR

IMPAX receives final FDA approval for generic version of Sinemet CR